These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 22238368

  • 1. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [Abstract] [Full Text] [Related]

  • 2. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

  • 3. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
    Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, Martin AM, Gilmer TM.
    Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
    [Abstract] [Full Text] [Related]

  • 4. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [Abstract] [Full Text] [Related]

  • 5. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.
    Oncogene; 2014 Jun 19; 33(25):3334-41. PubMed ID: 23873022
    [Abstract] [Full Text] [Related]

  • 6. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
    Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.
    Exp Mol Med; 2013 Nov 22; 45(11):e64. PubMed ID: 24263233
    [Abstract] [Full Text] [Related]

  • 7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Nov 22; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 8. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J.
    Clin Cancer Res; 2014 Sep 01; 20(17):4559-73. PubMed ID: 24973425
    [Abstract] [Full Text] [Related]

  • 9. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J, Choi Y, Ko YS, Kim Y, Pyo JS, Jang BG, Kim MA, Lee JS, Chang MS, Park JW, Lee BL.
    Cancer Res Treat; 2018 Jan 01; 50(1):239-254. PubMed ID: 28343375
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV, Reginato MJ.
    Oncotarget; 2015 Feb 10; 6(4):1967-80. PubMed ID: 25596742
    [Abstract] [Full Text] [Related]

  • 11. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 12. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 13. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H.
    Gastric Cancer; 2014 Jan 28; 17(3):450-62. PubMed ID: 23948998
    [Abstract] [Full Text] [Related]

  • 14. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

  • 15. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    Ning G, Zhu Q, Kang W, Lee H, Maher L, Suh YS, Michaud M, Silva M, Kwon JY, Zhang C, Lee C.
    BMC Cancer; 2021 Aug 16; 21(1):923. PubMed ID: 34399705
    [Abstract] [Full Text] [Related]

  • 16. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
    Bai M, Song N, Che X, Wang X, Qu X, Liu Y.
    Cell Biol Int; 2018 Jul 16; 42(7):781-793. PubMed ID: 29271513
    [Abstract] [Full Text] [Related]

  • 17. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.
    PLoS One; 2017 Jul 16; 12(2):e0171356. PubMed ID: 28158234
    [Abstract] [Full Text] [Related]

  • 18. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
    De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H.
    Br J Cancer; 2015 Nov 03; 113(9):1305-12. PubMed ID: 26484410
    [Abstract] [Full Text] [Related]

  • 19. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.
    PLoS One; 2010 Feb 02; 5(2):e9024. PubMed ID: 20126311
    [Abstract] [Full Text] [Related]

  • 20. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
    Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL.
    Ann Thorac Surg; 2018 Feb 02; 105(2):363-370. PubMed ID: 29223420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.